Harvard’s CRISPR pioneer, Chad Cowan has signed on to handle the preclinical work for new drugs slated to join the pipeline at a well-financed Mustang Bio.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
Christmas shoppers in search of a thoughtful gift that “is personal and says a lot” about the recipient may have just outdone themselves.
Multi-billion $ losses to the global shrimp industry, together with devastating impacts on local livelihoods, could be eradicated using DNA technology.
With 2017 coming to a close, the biopharma industry and the US Food and Drug Administration (FDA) are preparing to face a very busy time.
The Medicines Company is selling its infectious disease business unit to Melinta Therapeutics for $270 million.
President Donald Trump’s selected candidate for the Department of Health and Human Services will face a confirmation hearing.
NanoCellect Biomedical today announced the completion of a $10 million Series B financing round, including convertible notes.
Johnson & Johnson remain hesitant to go ahead with plans to open new R&D facility, after rising economy concerns in the UK.
Illumina is opening its first Customer Solutions Center in France, where it will train up to 1,000 scientists a year in latest genomics technologies.
Medicare and insurers struggle to oversee a booming business in testing urine samples. In some cases, pain doctors’ lack of follow-through can turn fatal.
Ahead of Brexit, the government are pushing for growth in the pharma sector through investments in R&D, and infrastructure.
Novartis has revealed plans to potentially snatch some patients from GlaxoSmithKline with Advair rival Ultibro Breezhaler.